Rituximab Plus CEAC: No Survival Advantage in DLBCL
In the evolving landscape of oncology, particularly targeting hematological malignancies, innovative therapeutic strategies consistently attract significant attention. A recent pivotal ...
In the evolving landscape of oncology, particularly targeting hematological malignancies, innovative therapeutic strategies consistently attract significant attention. A recent pivotal ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine